Retrospective analysis of local recurrence rate in breast cancer patients treated at the department of surgical oncology in Łódź between 2009 and 2013
Languages of publication
The aim of the study was to analyze clinicopathological features in breast cancer patients with local recurrence (LR). Material and methods. A retrospective analysis of database of breast cancer patients operated on in the Department of Surgical Oncology in Łódź from 2 January 2009 to 30 June 2013, identified 1080 women with primary breast cancer and 11 patients with LR. Results. LR rate was 0.23% per year. True recurrence (TR) occurred more frequently in patients with luminal B molecular subtype, in HER-2 positive and in triple-negative subgroups. In one patient with luminal -A subtype new primary (triple negative) occurred. TR were noted predominantly in patients with axillary lymph nodes metastases and with luminal B subtype who did not receive adjuvant chemotherapy but were given only endocrine therapy. LR were observed more frequently in patients who did not receive adjuvant radiotherapy or this treatment was delayed. Minimal surgical margins in postoperative specimens measured by pathologist were 4-25 mm, mean 9.5 mm. Conclusions. The LR rate in patients operated on breast cancer in the Department of Surgical Oncology between 2009 and 2013 was low. TR was diagnosed in patients with non- luminal A breast cancer despite wide surgical margins, especially if the patients did not receive optimal adjuvant systemic treatment or radiotherapy was delayed or omitted. Complete cancer excision followed by an immediate implementation of optimal adjuvant treatment seems to be crucial especially in patients with poor tumor biology.
1 - 02 - 2014
25 - 03 - 2014
- 1. www.eusoma.org
- 2. Aebi S, Davidson T, Gruber G et al.: ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 Suppl 6: vi12-24.[Crossref]
- 3. West NR, Panet-Raymond V, Truong PT et al.: Intratumoral immune response can distinguish new primary and true recurrence types of ipsilateral breast tumor recurrence. Breast Cancer: Basic and Clinical Research 2011; 5: 105-15.
- 4. Gerlinger M, Rowan AJ, Horswell S et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.[WoS]
- 5. Ho A, Morrow M: The evolution of the locoregional therapy of breast cancer. Oncologist 2011; 16: 1367-79.[WoS][Crossref][PubMed]
- 6. Morrow M, Harris JR, Schnitt SJ: Surgical margins in lumpectomy for breast cancer-bigger is not better. N Engl J Med 2012; 367: 79-82.[WoS]
- 7. Andrè Curigliano G, Criscitiello C, Colleoni M et al.: Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? Ecancermedicalscience 2013; 7: 299.
- 8. Fisher B, Dignam J, Mamounas EP et al.: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982-92.
- 9. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
- 10. Bischoff J, Ignatov A: The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.Breast Care (Basel) 2010; 5: 134-41.[WoS][Crossref]
- 11. Goldhirsch A, Wood WC, Coates AS et al.: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.[WoS][Crossref]
- 12. Nguyen PL, Taghian AG, Katz MS et al.: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-78.
- 13. Mazouni C, Rimareix F, Mathieu MC et al.: Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg 2013; 205: 662-67.[WoS]
- 14. Kyndi M, Sørensen FB, Knudsen H et al.: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-26.[PubMed][WoS]
- 15. Mamounas EP, Tang G, Fisher B et al.: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-83.[Crossref]
- 16. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al.: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet 2011; 378: 1707-16.[WoS]
- 17. Zumsteg ZS, Morrow M, Arnold B et al.: Breast- Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Ann Surg Oncol 2013 May 19. (Epub ahead of print).[WoS]
- 18. Willis L, Graham TA, Alarcón T et al.: What can be learnt about disease progression in breast cancer dormancy from relapse data? PLoS One 2013; 8: e62320.[Crossref][WoS]
Publication order reference